%0 Journal Article
%T Effects of Exenatide vs. Metformin on endothelial function in obese patients with pre-diabetes: a randomized trial
%A Aaron S Kelly
%A Richard M Bergenstal
%A J Gonzalez-Campoy
%A Harold Katz
%A Alan J Bank
%J Cardiovascular Diabetology
%D 2012
%I BioMed Central
%R 10.1186/1475-2840-11-64
%X We performed a randomized, open-label, clinical trial in 50 non-diabetic individuals (mean age 58.5 ¡À 10.0; 38 females) with abdominal obesity and either impaired fasting glucose, elevated HbA1c, or impaired glucose tolerance (IGT) who were randomized to receive 3-months of exenatide or metformin. Microvascular endothelial function, assessed by digital reactive hyperemia (reactive hyperemic index: RHI), C-reactive protein (CRP), circulating oxidized LDL (oxLDL), and vascular cell adhesion molecule-1 (VCAM-1) were measured at baseline and 3-months. Seven subjects with IGT participated in a sub-study comparing the effects of pre-administration of exenatide and metformin on postprandial endothelial function.There were no differences for the change in RHI (¦¤ exenatide: 0.01 ¡À 0.68 vs. ¦¤ metformin: -0.17 ¡À 0.72, P = 0.348), CRP, oxLDL, or VCAM-1 between exenatide and metformin treatment. Triglycerides were reduced more with exenatide compared to metformin (¦¤ exenatide: -25.5 ¡À 45.7 mg/dL vs. ¦¤ metformin: -2.9 ¡À 22.8 mg/dL, P = 0.032). In the sub-study, there was no difference in postprandial RHI between exenatide and metformin.Three months of exenatide therapy had similar effects on microvascular endothelial function, markers of inflammation, oxidative stress, and vascular activation, as metformin, in patients with obesity and pre-diabetes.This study is registered on http://www.clinicaltrials.gov/: NCT00546728 webciteThe term pre-diabetes is used to describe individuals with either impaired fasting glucose (IFG), elevated glycosylated hemoglobin (HbA1c), or impaired glucose tolerance (IGT). In parallel with the increase in the prevalence of obesity, the number of individuals with pre-diabetes is growing rapidly [1]. In addition to being predictive of type 2 diabetes mellitus (T2DM), pre-diabetes is associated with increased risk for developing cardiovascular disease (CVD) [2,3]. The preferred treatment approach for pre-diabetes is lifestyle modification emphasizing healt
%K Exenatide
%K Metformin
%K Endothelial function
%K Obesity
%K Pre-diabetes
%U http://www.cardiab.com/content/11/1/64